Organoprotective effects of serelaxin in patients with severe decompensated heart failure

• Main Authors: Z. D. Kobalava, S. V. Villevalde, A. E. Solov'jova, I. A. Merai
• Format: Article
• Language: English
• Published: Stolichnaya Izdatelskaya Kompaniya 2016-09-01
• Series: Racionalʹnaâ Farmakoterapiâ v Kardiologii
• Subjects: heart failure decompensation; serelaxin; cardio-hepatic syndrome; organoprotective effects
• Online Access: https://www.rpcardio.com/jour/article/view/1305
• ISSN: 1819-6446; 2225-3653

Serelaxin (recombinant molecule of the human relaxin-2) is an innovative drug for the treatment of acute heart failure. Preclinical and clinical studies demonstrated the ability of serelaxin to relieve the symptoms of heart failure, provide a significant reduction in congestion and have a protective effect on the heart, kidneys, liver. 48-hour serelaxin infusion in patient with ischemic cardiomyopathy and severe decompensated heart failure with cardio-hepatic syndrome led to significant regression of systemic congestion (evaluated by physical signs and by bioimpedance vector analysis), the improvement of structural and functional state of the myocardium (evaluated by standard echocardiography and global systolic longitudinal deformation of the left ventricle with speckle tracking echocardiography), regression of cardio-hepatic syndrome, improvement of renal function. Serelaxin therapy was well tolerated and was safe. Presented case report demonstrates beneficial effects of serelaxin on the heart failure symptoms and the organoprotective effects.